Fibroblast growth factor receptor 2 (FGFR2) is a membrane-spanning tyrosine kinase that mediates signaling for FGFs. Recent studies detected various point mutations of FGFR2 in multiple types of cancers, including breast cancer, lung cancer, gastric cancer, uterine cancer and ovarian cancer, yet the casual relationship between these mutations and tumorigenesis is unclear. Here we will discuss possible interactions between FGFR2 signaling and several major pathways through which the aberrantly activated FGFR2 signaling may result in breast cancer development. We will also discuss some recent developments in the discovery and application of therapies and strategies for breast cancers by inhibiting FGFR2 activities.
Keywords: Breast cancer, FGFR2, mutation, polymorphism, inhibitor.
Lei, H., Deng, C.X. (2017). Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer. International Journal of Biological Sciences, 13(9), 1163-1171. https://doi.org/10.7150/ijbs.20792.
Lei, H.; Deng, C.X. Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer. Int. J. Biol. Sci. 2017, 13 (9), 1163-1171. DOI: 10.7150/ijbs.20792.
Lei H, Deng CX. Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer. Int J Biol Sci 2017; 13(9):1163-1171. doi:10.7150/ijbs.20792. https://www.ijbs.com/v13p1163.htm
Lei H, Deng CX. 2017. Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer. Int J Biol Sci. 13(9):1163-1171.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.